NASD · Healthcare · Biotechnology · United Kingdom
Virax Biolabs Group Ltd is a micro cap company (market value under $300 million) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Virax Biolabs Group Ltd stock.
Undervalued: intrinsic value $4.59 per share, market price $1.21, margin of safety 73.6% (as of 2026-10-30).
A 2.4x revenue multiple, discounted for its losses, values the shares at $4.59; the price of $1.21 is 74% below that value.
VRAX is undervalued (as of the 2026-10-30 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $4.59; the price of $1.21 is 74% below that value.
$4.59 per share (as of the 2026-10-30 close), against a market price of $1.21. That is a margin of safety of 73.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.